Two cases of fatal systemic lupus erythematosus (SLE) with cerebral involvement are described. Both showed widespread microinfarction of the brain secondary to platelet and fibrin thrombi. There was no evidence of vasculitis. Anticoagulants and antiplatelet drugs may have an important role in the management of cerebral SLE.
Introduction
Coagulation abnormalities are a well recognized cause of cerebral complications in systemic diseases such as diabetes mellitus (Tim perley et al. 1974) . However, the cause of central nervous system (CNS) manifestations in SLE remains uncertain, although suggested factors include vasculitis (Johnson & Richardson 1968 ) and antineuronal antibodies (Bluestein & Zvaifler 1976) . We describe two cases of fatal SLE with cerebral involvement. Both were associated with severe coagulation abnormalities.
Case reports
Case 1: A 36-year-old woman presented with a history of numbness in the left arm, ataxia and dysarthria. Discoid lupus erythematosus had been diagnosed 12 years previously and arthralgia had developed at the age of 33 years. At that time the antinuclear factor was positive (I in 200) and LE cells were present. Treatment had been commenced and subsequently maintained with prednisolone. The presenting neurological symptoms partially resolved but admission was arranged following the development of drowsiness, irritability and severe headache.
Examination showed a left hemiparesis and a right facial weakness. Emergency investigations included: Hb 7.5 g/dl ; WCC 8.4 X 10 9/1; platelets less than 10 x 10 9 11and fibrin ,degradation products 32 Ilglml. A peripheral blood film suggested microangiopathic haemolysis and the serum complement levels were reduced (C3 0.75 gil; C4 0.16g/l; C3 proactivator 0.25 gil). CSF beta-thromboglobulin was grossly elevated (128 mg/ml) but CSF complement was not detectable. The antinuclear factor was again positive (l in 500) and antibodies against double-stranded DNA were present (I in 320). Treatment was commenced with platelet rich plasma, intravenous dexamethasome and hydrocortisone. Death occurred rapidly before platelet function tests were performed. Autopsy revealed widespread microinfarction of the brain secondary to platelet and fibrin thrombi ( Figure I) . The cerebral vessels showed no evidence of vasculitis and immunoperoxidase studies failed to show evidence of immune complex deposition. The kidney showed a mild focal segmental glomerulonephritis and the spleen showed periarterial fibrosis as seen in SLE. bilateral ulnar nerve palsies were present. The ESR was 115 mm/h (Westergren) and the antinuclear factor was positive (1 in 120). Antibodies against double-stranded DNA (1 in 340) and LE cells were present. The serum complement levels were reduced (C3 0.46 gil; C4 0.12 gil; C3 proactivator 0.27 gj\) and mixed IgG-IgM cryoglobulins were present (lgj\). The serum creatinine was 260 umol/l with a creatinine clearance of 57 ml/rnm and a urinary excretion of protein 2 gil. A renal biopsy showed a focal segmental glomerulonephritis with haematoxyphil bodies. Despite treatment with prednisolone, azothiaprine and plasma exchange, a progressive deterioration of mental function, speech and vision occurred over the next year. During the exacerbation of cerebral symptoms, serum and CSF C3 and C4 levels were less than I mg/l. Death occurred suddenly following a right hemiparesis. The platelet count at this time had fallen to 40 x lOt til and fibrin degradation products were elevated (64 ngyrnl).
Autopsy showed areas of both macro-and microinfarction in the brain secondary to platelet and fibrin thrombi. The cerebral vessels showed no evidence of vasculitis and immunofluorescent studies failed to show evidence of immune complex deposition. The spleen showed periarterial fibrosis.
Discussion
Johnson demonstrated that the most consistent histological finding in cases of SLE with CNS manifestations was the presence of cerebral infarction (Johnson & Richardson 1968) . Vasculitis is generally thought to be the most important factor in the causation of such ischaemic lesions but the same study failed to demonstrate inflammatory vascular disease in 10 out of 13 cases. Six cases showed cerebral infarction with no demonstrable vascular lesion and in two cases fibrin thrombi were present in the vessels. In the absence of careful coagulation studies, the possible significance of the latter findings may not have been realized. In a recent study of patients with SLE, changes in regional blood flow and oxygen-IS utilization were seen in 23 of 24 patients with definite CNS involvement (Pinching et al. 1978) . Such perfusion changes could be explained by coagulation abnormalities.
The immunological findings in both of the present cases are consistent with the activation of complement by the classical pathway. This has been associated with the initiation of both platelet aggregation (through the products C3a and C5a) and coagulation. The haematological results in the first case strongly suggest intravascular platelet aggregation and in the second case intravascular coagulation. This view is supported by the histological findings.
SLE has occasionally been reported to be associated with the clinical features of thrombotic thrombocytopenia purpura (Levine & Shearn 1964) , but detailed haematological studies were not performed. It is possible that the changes observed were a manifestation of coagulation abnormalities resulting from complement activation.
Anticoagulants and antiplatelet drugs may be useful in the treatment of cerebral SLE.
